| Literature DB >> 29636974 |
Pascal Vranckx1, Marco Valgimigli2, Hein Heidbuchel3.
Abstract
Vitamin K antagonists (VKAs) such as warfarin are the most commonly prescribed oral anticoagulants worldwide. However, factors affecting the pharmacokinetics of VKAs, such as food and drugs, can cause deviations from their narrow therapeutic window, increasing the bleeding or thrombosis risk and complicating their long-term use. The use of direct oral anticoagulants (DOACs) offers a safer and more convenient alternative to VKAs. However, it is important to be aware that plasma levels of DOACs are affected by drugs that alter the cell efflux transporter P-glycoprotein and/or cytochrome P450. In addition to these pharmacokinetic-based interactions, DOACs have the potential for pharmacodynamic interaction with antiplatelet agents and non-steroidal anti-inflammatory drugs. This is an important consideration in patient groups already at high risk of bleeding, such as patients with renal impairment.Entities:
Keywords: Apixaban; dabigatran; direct oral anticoagulants; drug—drug interactions; edoxaban; rivaroxaban; vitamin K antagonists; warfarin
Year: 2018 PMID: 29636974 PMCID: PMC5889806 DOI: 10.15420/aer.2017.50.1
Source DB: PubMed Journal: Arrhythm Electrophysiol Rev ISSN: 2050-3369